Management of Antipsychotic Treatment

Patient Assessment and Monitoring

The European Society of Cardiology notes that alterations in the QTc interval can occur with both medications, but aripiprazol has a lower risk 1
Patients with renal disease require consideration of lower initial doses of aripiprazol (2.5 mg) and slower titration, as recommended by the American Psychiatric Association, with a strength of evidence based on clinical trials 2
Elderly patients should be initiated on aripiprazol at 2.5 mg and have their dose increased more slowly, based on expert consensus from the American Geriatrics Society 2
The American College of Clinical Oncology recommends monitoring serum creatinine every 3-4 weeks initially, then quarterly, and watching for signs of worsening renal function 3
Avoiding medications that may worsen renal function, such as NSAIDs, is advised in patients with renal impairment by the American College of Clinical Oncology 3

Antipsychotic polypharmacy should be avoided when possible to minimize adverse effects, as recommended by the American Academy of Child and Adolescent Psychiatry 4
The American Academy of Child and Adolescent Psychiatry recommends assessing for involuntary movements to rule out tardive dyskinesia and considering switching to an SGA with lower risk of movement disorders if present 5
If muscle spasms are medication-related, considering dose reduction of current SGA if clinically feasible, and monitoring for akathisia is suggested by the American Academy of Child and Adolescent Psychiatry 5
Medication dosage should be periodically reassessed to ensure the lowest effective dose, as recommended by the American Academy of Child and Adolescent Psychiatry 5

Medication non-adherence is the strongest predictor of relapse, with relapse rates five times higher among those who discontinue medication, highlighting the importance of maintaining antipsychotic treatment, according to the British Journal of Psychiatry 6
High expressed emotion in family environments is associated with higher relapse rates, according to the American Academy of Child and Adolescent Psychiatry 5
Substance misuse strongly predicts medication non-adherence and is a significant risk factor for schizophrenia relapse, as stated by the Substance Abuse and Mental Health Services Administration 6
Regular assessment of medication adherence is crucial for preventing schizophrenia relapse, as recommended by the British Journal of Psychiatry guidelines 6
Weekly visits during medication changes or periods of instability can help prevent schizophrenia relapse, as recommended by the American Psychiatric Association 7

Patients and families should be educated about warning signs requiring immediate attention, such as unusual thoughts, suspiciousness, and perceptual changes, as stated by the National Alliance on Mental Illness and the National Institute of Mental Health 7, 7
Education should focus on evidence-based relapse indicators rather than cosmetic side effects, as recommended by the American Psychiatric Association 7
Family involvement is crucial in adherence strategies, as recommended by the British Journal of Psychiatry 6
Family intervention programs and psychoeducational interventions significantly decrease relapse rates and improve family functioning and problem-solving, as supported by evidence from the American Academy of Child and Adolescent Psychiatry 5

Emergency psychiatric evaluation is necessary if symptoms pose safety risks to self or others, as stated by The Lancet Psychiatry 2
Consideration of hospitalization is recommended if symptoms are severe or the patient is unable to cooperate with outpatient management, according to the American Journal of Psychiatry guidelines 8
Continuation of the LAI schedule while adding oral supplementation as needed is advised during hospitalization, based on the British Journal of Psychiatry recommendations 6
Prompt intervention is necessary before a crisis develops if a patient misses doses, according to the British Journal of Psychiatry guidelines 6